-
Subject Areas on Research
-
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
-
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
-
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
-
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
-
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
-
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
-
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
-
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
-
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
-
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
-
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
-
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
-
Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.
-
Alternating Electric Fields for the Treatment of Glioblastoma.
-
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
-
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
-
Anti-angiogenic therapy for high-grade glioma.
-
Antiangiogenic therapy for high-grade glioma.
-
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
-
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
-
Avastin: more questions than answers. .
-
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
-
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
-
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
-
Bevacizumab and daily temozolomide for recurrent glioblastoma.
-
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
-
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
-
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
-
Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy.
-
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
-
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
-
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
-
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
-
Cryptococcal meningitis in patients with glioma: a report of two cases.
-
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
-
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
-
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
-
Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations.
-
Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
-
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
-
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
-
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
-
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
-
Evolving management of low grade glioma: No consensus amongst treating clinicians.
-
Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
-
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
-
Genomic and molecular profiling predicts response to temozolomide in melanoma.
-
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
-
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
-
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
-
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
-
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
-
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
-
How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
-
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
-
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
-
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
-
In reply to Robins et al.
-
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
-
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
-
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
-
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
-
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
-
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
-
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
-
Long-term follow-up of survival in Hodgkin's lymphoma.
-
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
-
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
-
Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
-
MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
-
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
-
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
-
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
-
Management of glioblastoma: an Australian perspective.
-
Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy.
-
Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
-
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
-
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
-
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
-
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
-
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
-
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
-
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
-
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
-
Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
-
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
-
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
-
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
-
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
-
O6-benzylguanine-mediated enhancement of chemotherapy.
-
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
-
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.
-
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
-
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
-
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
-
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
-
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
-
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
-
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
-
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
-
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
-
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
-
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
-
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
-
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
-
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
-
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
-
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
-
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
-
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
-
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
-
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
-
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
-
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
-
Phase II trial of temozolomide in patients with progressive low-grade glioma.
-
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
-
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
-
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
-
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
-
Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone.
-
Recent advances in the treatment of malignant astrocytoma.
-
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
-
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
-
Reversing the Warburg effect as a treatment for glioblastoma.
-
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
-
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
-
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
-
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.
-
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
-
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
-
Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer.
-
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
-
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
-
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
-
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
-
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
-
Temozolomide and treatment of malignant glioma.
-
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
-
Temozolomide in children with progressive low-grade glioma.
-
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
-
Temozolomide in pediatric low-grade glioma.
-
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
-
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
-
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
-
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
-
The fallacy of single-agent chemotherapy for cancer.
-
The patient experience of ABVD treatment in Hodgkin lymphoma: a retrospective cohort study of patient-reported distress.
-
Treatment of neoplastic meningitis with intrathecal temozolomide.
-
Treatment of newly diagnosed glioblastoma multiforme.
-
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
-
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
-
Keywords of People